PharmaShots | Incisive News in 3 Shots

Subscribe Now

lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

February 2, 2021

$MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma$

MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or...

August 3, 2020

Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

June 16, 2020

Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell Lymphoma

Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell L...

January 21, 2020

$Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma$

Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma

June 11, 2019

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

May 29, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us